In addition to the steady flow of new cytotoxic drugs for lung cancer during the last decade, the elegant concept of targeted agents has in recent years become a source of optimism and pitfalls. Among all the targets, Her2-neu is a typical example of how preclinical data can be translated into clinical progress. Her2-neu in breast cancer: the ideal model Erb-B2 (Her2-neu) is a 185 kDa glycoprot...

Background: The prognostic factors for breast cancer include pretreatment staging, nodal and distant metastasis, hormone receptor status, ki67 index, molecular subtype. For adequate treatment, [18F]FDG PET/CT is now being used to prognosticate the course response of treatment in patients. Our study aims find association between metabolic activity primary tumors as SUV uptake such ER/PgR/Her2neu...

Purpose The purpose of this study was to report clinical outcomes in patients treated with accelerated partial breast irradiation (APBI), stratified as per molecular subtype and American Society for Therapeutic Radiology and Oncology/Groupe Européen de Curiethérapie and European Society for Radiotherapy & Oncology (ASTRO/GEC-ESTRO) patient selection criteria in order to determine whether molecu...

BACKGROUND Young age breast cancers are quite prevalent in our setup, a significant number of which exhibit triple negative phenotype. These cancers behave in an aggressive fashion and unresponsive to targeted adjuvant therapy. We aimed to evaluate clinical and histopathologic features of triple negative cancers in our population. METHODS We retrospectively evaluated 1104 cases of primary bre...

BACKGROUND The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IBC) is controversial. Cell proliferation, especially the Mitotic Activity Index (MAI), is strongly prognostic in lymph node-negative (LNneg) invasive breast cancer. However, its prognostic value has not been compared with the value of Akt and PTEN expression. MATERIAL AND METHODS Prognostic compa...

The successful application of human gene therapy protocols on a broad clinical basis will depend on the availability of in vivo cell-type-specific gene delivery systems. We have developed retroviral vector particles, derived from spleen necrosis virus (SNV), that display the antigen binding site of an antibody on the viral surface. Using retroviral vectors derived from SNV that displayed single...